About Deciphera
Deciphera is a company based in Waltham (United States) founded in 2003 was acquired by ONO PHARMACEUTICAL in April 2024.. Deciphera has raised $172.9 million across 3 funding rounds from investors including Lilly, New Leaf Venture Partners and ONO PHARMACEUTICAL. The company has 394 employees as of December 31, 2022. Deciphera offers products and services including Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009. Deciphera operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Waltham, United States
- Employees 394 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Deciphera Pharmaceuticals, Llc
-
Annual Revenue
$163.36 M22as on Dec 31, 2023
-
Net Profit
$-194.94 M-9as on Dec 31, 2023
-
EBITDA
$-210.96 M-15as on Dec 31, 2023
-
Total Equity Funding
$172.9 M (USD)
in 3 rounds
-
Latest Funding Round
$52.3 M (USD), Series C
Jun 05, 2017
-
Investors
Lilly
& 6 more
-
Employee Count
394
as on Dec 31, 2022
-
Acquired by
ONO PHARMACEUTICAL
(Apr 29, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Deciphera
Deciphera offers a comprehensive portfolio of products and services, including Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Kinase inhibitor targeting cancer growth and resistance
Kinase inhibitor for specific cancer treatments
Experimental kinase inhibitor in preclinical stages
Kinase inhibitor for oncology applications
Preclinical kinase inhibitor for cancer therapy
Unlock access to complete
Unlock access to complete
Leadership Team
66 people
Software Development Team
33 people
Operations Team
18 people
Senior Team
9 people
Sales and Marketing
7 people
Product Management Team
7 people
Human Resources and Administration
7 people
Finance and Accounting
6 people
Unlock access to complete
Funding Insights of Deciphera
Deciphera has successfully raised a total of $172.9M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $52.3 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $52.3M
-
First Round
First Round
(01 Apr 2014)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2017 | Amount | Series C - Deciphera | Valuation | Viking Global Investors , Redmile Group | |
| Jul, 2016 | Amount | Series B - Deciphera | Valuation | New Leaf Venture Partners | |
| Apr, 2014 | Amount | Series A - Deciphera | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Deciphera
Deciphera has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, New Leaf Venture Partners and ONO PHARMACEUTICAL. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Stage-agnostic investments in US life sciences are managed.
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on early-stage healthcare startups
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Deciphera
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Deciphera
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Deciphera Comparisons
Competitors of Deciphera
Deciphera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Deciphera
Frequently Asked Questions about Deciphera
When was Deciphera founded?
Deciphera was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Where is Deciphera located?
Deciphera is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Is Deciphera a funded company?
Deciphera is a funded company, having raised a total of $172.9M across 3 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Apr 01, 2014.
How many employees does Deciphera have?
As of Dec 31, 2022, the latest employee count at Deciphera is 394.
What is the annual revenue of Deciphera?
Annual revenue of Deciphera is $163.36M as on Dec 31, 2023.
What does Deciphera do?
Deciphera was founded in 2003 in Waltham, United States, within the biotechnology sector. A proprietary switch-control kinase inhibitor platform is utilized by the company, combined with expertise in kinase biology, to advance a portfolio of cancer therapies. Focus is placed on type 2 kinase inhibitors aimed at addressing unmet needs in oncology. Operations center on research and development for novel medicinal products in the United States.
Who are the top competitors of Deciphera?
Deciphera's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Deciphera offer?
Deciphera offers Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009.
Who are Deciphera's investors?
Deciphera has 7 investors. Key investors include Lilly, New Leaf Venture Partners, ONO PHARMACEUTICAL, Viking Global Investors, and Redmile Group.